Auteurs
Checkpoint
Ncbi
Racine
Checkpoint
Ncbi
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Graeme Jones »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Graciela González < Graeme Jones < Graham Dinsdale  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 13.
Ident.Authors (with country if any)Title
000000 (2003) Changhai Ding [Australie] ; Graeme JonesTechnology evaluation: MRA, Chugai.
000078 (2006) Changhai Ding [Australie] ; Graeme JonesAnti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
000172 (2009) Changhai Ding [Australie] ; Flavia Cicuttini ; Jun Li ; Graeme JonesTargeting IL-6 in the treatment of inflammatory and autoimmune diseases.
000233 (2010) Graeme Jones [Australie]The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis.
000334 (2010) Graeme Jones [Australie] ; Changhai DingTocilizumab: a review of its safety and efficacy in rheumatoid arthritis.
000627 (2012) Graeme Jones [Australie] ; Erica Darian-Smith ; Michael Kwok ; Tania WinzenbergEffect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
000685 (2012) Monika M. Schoels [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho M. Murikama [Japon] ; Norihiro Nishimoto [Japon] ; Josef S. Smolen [Autriche]Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
000692 (2012) Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas]Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
001003 (2016) Emma Mitchell [Australie] ; Graeme Jones [Australie]Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
001411 (2017) Graeme Jones [Espagne] ; Thomas Wallace [Espagne] ; Matthew J. Mcintosh [Espagne] ; Laura Brockwell [Espagne] ; Juan J. G Mez-Reino [Espagne] ; Anthony Sebba [Espagne]Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study.
001754 (2017) Vibeke Strand [États-Unis] ; Margaret Michalska [États-Unis] ; Christine Birchwood [États-Unis] ; Jinglan Pei [États-Unis] ; Katie Tuckwell [États-Unis] ; Rebecca Finch [Royaume-Uni] ; Cem Gabay [Suisse] ; Arthur Kavanaugh [États-Unis] ; Graeme Jones [Australie]Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
001849 (2018) Graeme Jones [Australie] ; Stephen Hall [Australie] ; Paul Bird [Australie] ; Geoff Littlejohn [Australie] ; Kathleen Tymms [Australie] ; Peter Youssef [Australie] ; Eric Chung [Australie] ; Rina Barrett [Australie] ; Peter Button [Australie]A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
001C48 (2018) Graeme Jones [Australie] ; Elena Panova [Australie]New insights and long-term safety of tocilizumab in rheumatoid arthritis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Graeme Jones" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Graeme Jones" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Graeme Jones
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021